Gilead (GILD) Q2 FY26 earnings call

Gilead delivered a strong second quarter, marked by robust commercial execution across its core therapeutic areas, particularly in HIV and oncology. The company raised its full-year HIV growth expectations and advanced its extensive pipeline through strategic acquisitions and positive clinical readouts. Management remains focused on integrating new programs and preparing for several key product launches in the near term, while continuing to diversify its portfolio.